SCFA contribute to slowing the progression of DKD by affecting the immune system, modulating the anti-inflammatory response, sealing the intestinal barrier, increasing GLP-1 levels, lowering the intestinal pH, and reducing oxidative stress. Here, GLP1R is linked to diabetic kidney disease.